Sarepta Therapeutics (SRPT) Change in Receivables (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Change in Receivables of -$3.4 million for Q1 2026, down 105.95% year-over-year from $57.4 million in Q1 2025, and down 236.97% quarter-over-quarter from $2.5 million in Q4 2025.
Sarepta Therapeutics (SRPT) Change in Receivables (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Change in Receivables history runs 17 years deep, the most recent figure standing at -$3.4 million for Q1 2026.
- In Q1 2026, Change in Receivables fell 105.95% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$264.6 million (down 194.29% YoY), while the FY2025 annual figure was -$203.8 million, down 201.04% from the prior year.
- Change in Receivables for Q1 2026 stood at -$3.4 million, down from $2.5 million in the prior quarter.
- The five-year high for Change in Receivables was $167.5 million in Q4 2024, with the low at -$132.1 million in Q2 2025.
- The 5-year median for Change in Receivables is $13.0 million (2023), against an average of $14.2 million.
- The sharpest annual moves came in 2023 and 2025: Change in Receivables soared 3598.81% in 2023, then sank 602.2% in 2025.
- Sarepta Therapeutics' Change in Receivables stood at $13.1 million in 2022, then jumped by 521.02% to $81.5 million in 2023, then soared by 105.55% to $167.5 million in 2024, then plunged by 98.51% to $2.5 million in 2025, then plunged by 236.97% to -$3.4 million in 2026.
- Business Quant data shows SRPT's Change in Receivables at -$3.4 million in Q1 2026, $2.5 million in Q4 2025, and -$131.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | -17.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.99 Mn |
| Jun 30, 2026 | -17.99 Mn |
| Mar 31, 2026 | -3.42 Mn |
| Mar 31, 2026 | -3.42 Mn |
| Dec 31, 2025 | 2.49 Mn |
| Dec 31, 2025 | 2.49 Mn |
| Sep 30, 2025 | -131.56 Mn |
| Sep 30, 2025 | -131.56 Mn |
| Jun 30, 2025 | -132.08 Mn |
| Jun 30, 2025 | -132.08 Mn |
| Mar 31, 2025 | 57.38 Mn |
| Mar 31, 2025 | 57.38 Mn |
| Dec 31, 2024 | 167.46 Mn |
| Dec 31, 2024 | 167.46 Mn |
| Sep 30, 2024 | 74.53 Mn |
| Sep 30, 2024 | 74.53 Mn |
| Jun 30, 2024 | -18.81 Mn |
| Jun 30, 2024 | -18.81 Mn |
| Mar 31, 2024 | -21.52 Mn |
| Mar 31, 2024 | -21.52 Mn |